title: [The influence and safety of denosumab on bone mineral density of lumbar spine in women with low bone mass: a meta-analysis].
abstract: OBJECTIVE
  To evaluate the influence and safety of denosumab on bone mineral density (BMD) of lumbar spine in women with low bone mass.
  
  
  METHODS
  The clinical literatures concerning denosumab for the treatment of osteopenia or osteoporosis in women were searched from Medline, Embase, Cochrane Central Register of Controlled Trials, Wanfang database, China National Knowledge Infrastructure database, Chinese Biomedical Database. Randomized controlled trials (RCT) were selected by the inclusive and exclusive criteria. The jadad scale was used in the quality assessment of included studies. Meta-analysis of valid data picked from included studies was performed by RevMan 5.0.24 software.
  
  
  RESULTS
  5 RCT were included in this meta-analysis. The results of meta-analysis using the fixed effects model showed that, the increase level of lumbar BMD after 12 month was 5.45% (95% CI, 5.05%~5.84%) higher in denosumab group than in placebo control group (P<0.00001). The serious adverse event, serious infection event and pack pain occurred during the followed-up were analysed using fixed effects model. The results showed no significant difference between two groups.
  
  
  CONCLUSIONS
  Compared with placebo control group, denosumab can significant increase the BMD of lumbar spine, and the safety of two groups is similar.
authors.affiliation: Department of Spine Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. rimfk@126.com
authors.forename: Xiaowen
authors.initials: X
authors.lastname: Zhu
authors.forename: Jianting
authors.initials: J
authors.lastname: Chen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology; D000069448:Denosumab; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae; D016032:Randomized Controlled Trials as Topic
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab